scholarly journals Exploring the Role of Mesenchymal Stem Cells During Normothermic Organ Perfusion: A New Paradigm to Enhance Outcome Following Allograft Transplantation

2018 ◽  
Vol 5 (1) ◽  
pp. 47-52
Author(s):  
Mohamed Morsy ◽  
Mohammad Ayaz Hossain ◽  
Atul Bagul
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Organ Transplantation ◽  
Ex Vivo ◽  
Solid Organ Transplantation ◽  
Short Review ◽  
Solid Organ ◽  
New Paradigm ◽  
Liver And Kidney

Background: Normothermic Machine Perfusion (NMP) has been established in the field of solid organ transplantation for both liver and kidney allografts. The ability to perfuse organs at body temperature enables viability assessment as well as optimisation prior to implantation. Discussion: A recent in vitro report of the use of Mesenchymal Stem Cells (MSCs) in the use of a normothermic lung perfusion circuit has raised the possibility of their use in solid organ transplantation. The aim of this short review is to outline the potential uses of bone marrow derived MSCs for their use in renal allograft ex vivo NMP. An overview is provided of current literature of NMP as well as theorised uses for MSCs.

Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation

2009 ◽  
Vol 22 (4) ◽  
pp. 365-376 ◽  
Author(s):  
Meindert Crop ◽  
Carla Baan ◽  
Willem Weimar ◽  
Martin Hoogduijn
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Organ Transplantation ◽  
Immune Therapy ◽  
Solid Organ Transplantation ◽  
Solid Organ

scholarly journals Application of Mesenchymal Stem Cells During Machine Perfusion: An Emerging Novel Strategy for Organ Preservation

2021 ◽  
Vol 12 ◽  
Author(s):  
Jiale Li ◽  
Qinbao Peng ◽  
Ronghua Yang ◽  
Kunsheng Li ◽  
Peng Zhu ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Organ Transplantation ◽  
Organ Preservation ◽  
Ischemia Reperfusion ◽  
Solid Organ Transplantation ◽  
Therapeutic Effects ◽  
Solid Organ ◽  
Machine Perfusion ◽  
Marginal Grafts

Although solid organ transplantation remains the definitive management for patients with end-stage organ failure, this ultimate treatment has been limited by the number of acceptable donor organs. Therefore, efforts have been made to expand the donor pool by utilizing marginal organs from donation after circulatory death or extended criteria donors. However, marginal organs are susceptible to ischemia-reperfusion injury (IRI) and entail higher requirements for organ preservation. Recently, machine perfusion has emerged as a novel preservation strategy for marginal grafts. This technique continually perfuses the organs to mimic the physiologic condition, allows the evaluation of pretransplant graft function, and more excitingly facilitates organ reconditioning during perfusion with pharmacological, gene, and stem cell therapy. As mesenchymal stem cells (MSCs) have anti-oxidative, immunomodulatory, and regenerative properties, mounting studies have demonstrated the therapeutic effects of MSCs on organ IRI and solid organ transplantation. Therefore, MSCs are promising candidates for organ reconditioning during machine perfusion. This review provides an overview of the application of MSCs combined with machine perfusion for lung, kidney, liver, and heart preservation and reconditioning. Promising preclinical results highlight the potential clinical translation of this innovative strategy to improve the quality of marginal grafts.

Aneuploidy in Mesenchymal Stem Cells Cultured for Clinical Application in Solid Organ Transplantation: Hazard or not to Worry?

2012 ◽  
Vol 94 (10S) ◽  
pp. 1015
Author(s):  
M. Roemeling-van Rhijn ◽  
A. de Klein ◽  
H. Douben ◽  
J. N.M. IJzermans ◽  
C. C. Baan ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Organ Transplantation ◽  
Clinical Application ◽  
Solid Organ Transplantation ◽  
Solid Organ ◽  
Cells Cultured

scholarly journals Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting

2013 ◽  
Vol 96 (3) ◽  
pp. 234-238 ◽  
Author(s):  
Marcella Franquesa ◽  
Martin J. Hoogduijn ◽  
Marlies E. Reinders ◽  
Elke Eggenhofer ◽  
Anja U. Engela ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Organ Transplantation ◽  
Solid Organ Transplantation ◽  
Solid Organ

Solid Organ Transplantation in HIV-Infected Individuals

2017 ◽  
Author(s):  
Eurides Lopes ◽  
Jennifer Husson
Keyword(s):  
Organ Transplantation ◽  
Opportunistic Infections ◽  
Solid Organ Transplantation ◽  
Team Approach ◽  
Solid Organ ◽  
Hiv Disease ◽  
Transplant Recipients ◽  
Post Transplant ◽  
Liver And Kidney ◽  
Infectious Disease Specialists

End-organ disease has become a major cause of morbidity and mortality in HIV-infected patients due to increased life expectancy, increasing the demand for organ transplantation in these patients. The care of HIV-infected transplant recipients warrants a multidisciplinary team approach, including the transplant team, pharmacists, infectious disease specialists, nurses, and patients and their families. The immunosuppression of HIV-infected recipients post-transplant does not appear to further advance HIV disease. The post-transplant risk for HIV-infected recipients of opportunistic infections does not appear to be increased by immunosuppression. However, the overall rate of infections is high, and it is even higher in hepatitis C virus (HCV) co-infected transplant recipients. HIV/HCV co-infected recipients have worse outcomes compared to both liver and kidney HIV-infected recipients.

Human Mesenchymal Stem Cells Inhibit In Vitro Antibody Production Against Alloantigens.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 3033-3033
Author(s):  
Patrizia Comoli ◽  
Rita Maccario ◽  
Maria Antonietta Avanzini ◽  
Fabrizio Ginevri ◽  
Antonia Moretta ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
B Cell ◽  
Antibody Production ◽  
Third Party ◽  
Favourable Effect ◽  
Solid Organ ◽  
Hematopoietic Stem ◽  
Cross Match

Abstract Antibodies directed against alloantigens are implicated in the pathogenesis of several immune reactions complicating transplantation. In particular, this humoral response unfavorably affects the outcome of solid organ transplantation, and it has been hypothesized to be responsible for some of the clinical manifestations related to graft-versus-host disease (GVHD). In detail, the presence of antibodies against donor cells is a contraindication to kidney transplantation because of the risk of hyperacute rejection. In the effort to expand the donor pool, trials of allograft transplantation across HLA-sensitization have been conducted by means of strategies including pre-transplant plasmapheresis, intravenous immunoglobulins (Ig), anti-B cell monoclonal antibodies and splenectomy, associated with high-intensity immunosuppressive regimens. These measures have proved only partially successful in preventing humoral rejection in high-risk patients. Thus, the development of new therapeutic tools able to blunt alloantibody production could be a welcomed implementation to existing protocols. Mesenchymal stem cells (MSC) have been demonstrated to possess immunomodulatory capacity, since they induce T-cell hyporesponsiveness in vitro, prolong survival of skin graft in a primate model, and seem to decrease GVHD incidence and severity in humans given hematopoietic stem cell transplantation. To verify whether MSC may exert an inhibitory effect on antibody production, we stimulated B-cell-enriched peripheral blood mononuclear cells (PBMC) obtained from healthy controls (n=9) or sensitized prospective kidney recipients (n=5) in a mixed lymphocyte culture (MLC) against irradiated HLA-disparate stimulator PBMC (controls) or stimulators cells bearing HLA antigens matched with the positive cross-match (patients). Antibody production in the absence or in the presence of third-party allogeneic MSC (responder:MSC ratio:4:1) was then evaluated by ELISA. We found that the addition of MSC at the beginning of MLC considerably inhibited IgG and IgM production (median fold-decrease of IgG production: controls, 7; patients, 5; median fold-decrease of IgM production: controls, 17; patients, 4). Our preliminary findings indicate that third-party MSC are able to suppress antibody production in vitro, and may therefore help to overcome a positive cross-match in sensitized transplant recipients. These results may also contribute to partly explain the mechanism at the basis of the favourable effect played by MSC in patients with GVHD.

Thermoreversible hyaluronan-based hydrogel supports in vitro and ex vivo disc-like differentiation of human mesenchymal stem cells

2013 ◽  
Vol 13 (11) ◽  
pp. 1627-1639 ◽  
Author(s):  
Marianna Peroglio ◽  
David Eglin ◽  
Lorin M. Benneker ◽  
Mauro Alini ◽  
Sibylle Grad
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Ex Vivo ◽  
Human Mesenchymal Stem Cells
Sign in / Sign up

Export Citation Format

Share Document